In a precedential opinion issued on October 11, 2017, the United States Court of Appeals for the Federal Circuit reversed the Patent Trial and Appeals Board’s (“PTAB”) finding of non-obviousness where the prior art taught...more
On July 17, 2017, the United States Court of Appeals for the Federal Circuit reversed, in a precedential opinion in Millennium Pharmaceuticals, Inc. v. Sandoz, Inc., No. 2015-2066 (Fed. Cir. July 17, 2017), a district court...more
7/26/2017
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
FDA Approval ,
Generic Drugs ,
Obviousness ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Prescription Drugs ,
Prior Art ,
Sandoz
On March 3, 2017, the United States Court of Appeals for the Federal Circuit reaffirmed, in a precedential opinion, that prosecution disclaimers may only limit the scope of a claim where the disclaimer is “both clear and...more
On Monday, January 9, 2017, the U.S. Supreme Court denied, without comment, Mylan Pharmaceuticals’ petition for certiorari to reverse an opinion by the Court of Appeals for the Federal Circuit, which affirmed a broad scope of...more
Plaintiffs bringing patent infringement complaints under the Iqbal/Twombly pleading standard should take notice. On September 30, 2016, a panel of the Federal Circuit affirmed a district court’s dismissal of a deficient...more
10/13/2016
/ CAFC ,
CBS ,
Federal Rule 12(b)(6) ,
Joint Infringement ,
Limelight v Akamai ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pleading Standards ,
Television Broadcast Stations ,
Twombly/Iqbal Pleading Standard
On Friday, March 18, the Court of Appeals for the Federal Circuit affirmed two District of Delaware rulings that non-resident defendant generic ANDA filer, Mylan, is subject to personal jurisdiction in two Hatch-Waxman suits...more
We are excited to present you with the second issue of Israel Connect — our quarterly newsletter focused on forging new connections and strengthening existing bonds between Israeli businesses and the US market. In our second...more
2/11/2016
/ Anti-Competitive ,
Biosimilars ,
D&O Insurance ,
Department of Justice (DOJ) ,
Food and Drug Administration (FDA) ,
Individual Accountability ,
Israel ,
Law Practice Management ,
Mobile Apps ,
Off-Label Promotion ,
Precision Medicine Initiative (PMI) ,
U.S. Embassies ,
Visa Applications ,
Visas ,
White Collar Crimes ,
Yates Memorandum
On Monday, January 4, the Court of Appeals for the Federal Circuit heard oral argument in two appeals that may determine what effect the Supreme Court’s Daimler AG v. Bauman decision will have on the exercise of personal...more
The United States Supreme Court’s recent decision in Commil v. Cisco held that a good-faith belief of a patent’s invalidity, standing alone, is insufficient to provide a defense to a claim of inducing another’s infringement...more
8/3/2015
/ Cisco ,
Cisco v CommilUSA ,
Clear and Convincing Evidence ,
Good Faith ,
Honest Belief Defense ,
Induced Infringement ,
Patent Infringement ,
Patent Invalidity ,
Patents ,
SCOTUS ,
Standard of Review ,
Willful Infringement